Air Traffic and Operational Data on Selected US Airports with Parallel Runways

This report presents information on a number of airports in the country with parallel runways and focuses on those that have at least one pair of parallel runways closer than 4300 ft. Information contained in the report describes the airport's current operational activity as obtained through contact with the facility and from FAA air traffic tower activity data for FY 1997. The primary reason for this document is to provide a single source of information for research to determine airports where Airborne Information for Lateral Spacing (AILS) technology may be applicable

A convenient approach to characterizing model uncertainty with application to early dark energy solutions of the Hubble tension

Despite increasingly precise observations and sophisticated theoretical models, the discrepancy between measurements of H0 from the cosmic microwave background or from Baryon Acoustic Oscillations combined with Big-Bang Nucleosynthesis versus those from local distance ladder probes -- commonly known as the $H_0$ tension -- continues to perplex the scientific community. To address this tension, Early Dark Energy (EDE) models have been proposed as alternatives to $\Lambda$CDM, as they can change the observed sound horizon and the inferred Hubble constant from measurements based on this. In this paper, we investigate the use of Bayesian Model Averaging (BMA) to evaluate EDE as a solution to the H0 tension. BMA consists of assigning a prior to the model and deriving a posterior as for any other unknown parameter in a Bayesian analysis. BMA can be computationally challenging in that one must approximate the joint posterior of both model and parameters. Here we present a computational strategy for BMA that exploits existing MCMC software and combines model-specific posteriors post-hoc. In application to a comprehensive analysis of cosmological datasets, we quantify the impact of EDE on the H0 discrepancy. We find an EDE model probability of $\sim$90% whenever we include the H0 measurement from Type Ia Supernovae in the analysis, whereas the other data show a strong preference for the standard cosmological model. We finally present constraints on common parameters marginalized over both cosmological models. For reasonable priors on models with and without EDE, the H0 tension is reduced by at least 20%

The Stellar Content of Obscured Galactic Giant H II Regions IV.: NGC3576

We present deep, high angular resolution near-infrared images of the obscured Galactic Giant H II region NGC3576. Our images reach objects to ~3M_sun. We collected high signal-to-noise K-band spectra of eight of the brightest objects, some of which are affected by excess emission and some which follow a normal interstellar reddening law. None of them displayed photospheric features typical of massive OB type stars. This indicates that they are still enshrouded in their natal cocoons. The K-band brightest source (NGC3576 #48) shows CO 2.3 micron bandhead emission, and three others have the same CO feature in absorption. Three sources display spatially unresolved H_2 emission, suggesting dense shocked regions close to the stars. We conclude that the remarkable object NGC3576 #48 is an early-B/late-O star surrounded by a thick circumstellar disk. A number of other relatively bright cluster members also display excess emission in the K-band, indicative of reprocessing disks around massive stars (YSOs). Such emission appears common in other Galactic Giant H II regions we have surveyed. The IMF slope of the cluster, Gamma = -1.51, is consistent with Salpeter's distribution and similar to what has been observed in the Magellanic Cloud clusters and in the periphery of our Galaxy.Comment: 14 pages, 11 figures, accepted for publication in A

GASP II. A MUSE view of extreme ram-pressure stripping along the line of sight: kinematics of the jellyfish galaxy JO201

This paper presents a spatially-resolved kinematic study of the jellyfish galaxy JO201, one of the most spectacular cases of ram-pressure stripping (RPS) in the GASP (GAs Stripping Phenomena in Galaxies with MUSE) survey. By studying the environment of JO201, we find that it is moving through the dense intra-cluster medium of Abell 85 at supersonic speeds along our line of sight, and that it is likely accompanied by a small group of galaxies. Given the density of the intra-cluster medium and the galaxy's mass, projected position and velocity within the cluster, we estimate that JO201 must so far have lost ~50% of its gas during infall via RPS. The MUSE data indeed reveal a smooth stellar disk, accompanied by large projected tails of ionised (Halpha) gas, composed of kinematically cold (velocity dispersion <40km/s) star-forming knots and very warm (>100km/s) diffuse emission which extend out to at least ~50 kpc from the galaxy centre. The ionised Halpha-emitting gas in the disk rotates with the stars out to ~6 kpc but in the disk outskirts becomes increasingly redshifted with respect to the (undisturbed) stellar disk. The observed disturbances are consistent with the presence of gas trailing behind the stellar component, resulting from intense face-on RPS happening along the line of sight. Our kinematic analysis is consistent with the estimated fraction of lost gas, and reveals that stripping of the disk happens outside-in, causing shock heating and gas compression in the stripped tails.Comment: ApJ, revised version after referee comments, 15 pages, 16 figures. The interactive version of Figure 9 can be viewed at web.oapd.inaf.it/gasp/publications.htm

Probiotics for people with hepatic encephalopathy

Background Hepatic encephalopathy is a disorder of brain function as a result of liver failure or portosystemic shunt or both. Both hepatic encephalopathy (clinically overt) and minimal hepatic encephalopathy (not clinically overt) significantly impair patient’s quality of life and daily functioning, and represent a significant burden on healthcare resources. Probiotics are live micro‐organisms, which when administered in adequate amounts, may confer a health benefit on the host. Objectives To determine the beneficial and harmful effects of probiotics in any dosage, compared with placebo or no intervention, or with any other treatment for people with any grade of acute or chronic hepatic encephalopathy. This review did not consider the primary prophylaxis of hepatic encephalopathy. Search methods We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, conference proceedings, reference lists of included trials, and the World Health Organization International Clinical Trials Registry Platform until June 2016. Selection criteria We included randomised clinical trials that compared probiotics in any dosage with placebo or no intervention, or with any other treatment in people with hepatic encephalopathy. Data collection and analysis We used standard methodological procedures expected by The Cochrane Collaboration. We conducted random‐effects model meta‐analysis due to obvious heterogeneity of participants and interventions. We defined a P value of 0.05 or less as significant. We expressed dichotomous outcomes as risk ratio (RR) and continuous outcomes as mean difference (MD) with 95% confidence intervals (CI). Main results We included 21 trials with 1420 participants, of these, 14 were new trials. Fourteen trials compared a probiotic with placebo or no treatment, and seven trials compared a probiotic with lactulose. The trials used a variety of probiotics; the most commonly used group of probiotic was VSL#3, a proprietary name for a group of eight probiotics. Duration of administration ranged from 10 days to 180 days. Eight trials declared their funding source, of which six were independently funded and two were industry funded. The remaining 13 trials did not disclose their funding source. We classified 19 of the 21 trials at high risk of bias. We found no effect on all‐cause mortality when probiotics were compared with placebo or no treatment (7 trials; 404 participants; RR 0.58, 95% CI 0.23 to 1.44; low‐quality evidence). No‐recovery (as measured by incomplete resolution of symptoms) was lower for participants treated with probiotic (10 trials; 574 participants; RR 0.67, 95% CI 0.56 to 0.79; moderate‐quality evidence). Adverse events were lower for participants treated with probiotic than with no intervention when considering the development of overt hepatic encephalopathy (10 trials; 585 participants; RR 0.29, 95% CI 0.16 to 0.51; low‐quality evidence), but effects on hospitalisation and change of/or withdrawal from treatment were uncertain (hospitalisation: 3 trials, 163 participants; RR 0.67, 95% CI 0.11 to 4.00; very low‐quality evidence; change of/or withdrawal from treatment: 9 trials, 551 participants; RR 0.70, 95% CI 0.46 to 1.07; very low‐quality evidence). Probiotics may slightly improve quality of life compared with no intervention (3 trials; 115 participants; results not meta‐analysed; low‐quality evidence). Plasma ammonia concentration was lower for participants treated with probiotic (10 trials; 705 participants; MD ‐8.29 μmol/L, 95% CI ‐13.17 to ‐3.41; low‐quality evidence). There were no reports of septicaemia attributable to probiotic in any trial. When probiotics were compared with lactulose, the effects on all‐cause mortality were uncertain (2 trials; 200 participants; RR 5.00, 95% CI 0.25 to 102.00; very low‐quality evidence); lack of recovery (7 trials; 430 participants; RR 1.01, 95% CI 0.85 to 1.21; very low‐quality evidence); adverse events considering the development of overt hepatic encephalopathy (6 trials; 420 participants; RR 1.17, 95% CI 0.63 to 2.17; very low‐quality evidence); hospitalisation (1 trial; 80 participants; RR 0.33, 95% CI 0.04 to 3.07; very low‐quality evidence); intolerance leading to discontinuation (3 trials; 220 participants; RR 0.35, 95% CI 0.08 to 1.43; very low‐quality evidence); change of/or withdrawal from treatment (7 trials; 490 participants; RR 1.27, 95% CI 0.88 to 1.82; very low‐quality evidence); quality of life (results not meta‐analysed; 1 trial; 69 participants); and plasma ammonia concentration overall (6 trials; 325 participants; MD ‐2.93 μmol/L, 95% CI ‐9.36 to 3.50; very low‐quality evidence). There were no reports of septicaemia attributable to probiotic in any trial. Authors' conclusions The majority of included trials suffered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’). Accordingly, we consider the evidence to be of low quality. Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but probiotics may lead to little or no difference in mortality. Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available evidence is very low. High‐quality randomised clinical trials with standardised outcome collection and data reporting are needed to further clarify the true efficacy of probiotics

The contribution of δ subunit-containing GABAA receptors to phasic and tonic conductance changes in cerebellum, thalamus and neocortex

We have made use of the delta subunit-selective allosteric modulator DS2 (4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridine-3-yl benzamide) to assay the contribution of delta-GABAARs to tonic and phasic conductance changes in the cerebellum, thalamus and neocortex. In cerebellar granule cells, an enhancement of the tonic conductance was observed for DS2 and the orthosteric agonist THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol). As expected, DS2 did not alter the properties of GABAA receptor-mediated inhibitory postsynaptic synaptic currents (IPSCs) supporting a purely extrasynaptic role for delta-GABAARs in cerebellar granule cells. DS2 also enhanced the tonic conductance recorded from thalamic relay neurons of the visual thalamus with no alteration in IPSC properties. However, in addition to enhancing the tonic conductance DS2 also slowed the decay of IPSCs recorded from layer II/III neocortical neurons. A slowing of the IPSC decay also occurred in the presence of the voltage-gated sodium channel blocker TTX. Moreover, under conditions of reduced GABA release the ability of DS2 to enhance the tonic conductance was attenuated. These results indicate that delta-GABAARs can be activated following vesicular GABA release onto neocortical neurons and that the actions of DS2 on the tonic conductance may be influenced by the ambient GABA levels present in particular brain regions

Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study

BACKGROUND: The European Medicines Agency (EMA) requires vaccine manufacturers to conduct enhanced real-time surveillance of seasonal influenza vaccination. The EMA has specified a list of adverse events of interest to be monitored. The EMA sets out 3 different ways to conduct such surveillance: (1) active surveillance, (2) enhanced passive surveillance, or (3) electronic health record data mining (EHR-DM). English general practice (GP) is a suitable setting to implement enhanced passive surveillance and EHR-DM. OBJECTIVE: This study aimed to test the feasibility of conducting enhanced passive surveillance in GP using the yellow card scheme (adverse events of interest reporting cards) to determine if it has any advantages over EHR-DM alone. METHODS: A total of 9 GPs in England participated, of which 3 tested the feasibility of enhanced passive surveillance and the other 6 EHR-DM alone. The 3 that tested EPS provided patients with yellow (adverse events) cards for patients to report any adverse events. Data were extracted from all 9 GPs' EHRs between weeks 35 and 49 (08/24/2015 to 12/06/2015), the main period of influenza vaccination. We conducted weekly analysis and end-of-study analyses. RESULTS: Our GPs were largely distributed across England with a registered population of 81,040. In the week 49 report, 15,863/81,040 people (19.57% of the registered practice population) were vaccinated. In the EPS practices, staff managed to hand out the cards to 61.25% (4150/6776) of the vaccinees, and of these cards, 1.98% (82/4150) were returned to the GP offices. Adverse events of interests were reported by 113 /7223 people (1.56%) in the enhanced passive surveillance practices, compared with 322/8640 people (3.73%) in the EHR-DM practices. CONCLUSIONS: Overall, we demonstrated that GPs EHR-DM was an appropriate method of enhanced surveillance. However, the use of yellow cards, in enhanced passive surveillance practices, did not enhance the collection of adverse events of interests as demonstrated in this study. Their return rate was poor, data entry from them was not straightforward, and there were issues with data reconciliation. We concluded that customized cards prespecifying the EMA's adverse events of interests, combined with EHR-DM, were needed to maximize data collection. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1136/bmjopen-2016-015469